Objective: Explore feasibility and acceptability of gentamicin in the Uniject prefilled injection system, in combination with oral cotrimoxazole-p and an appropriate newborn weighing scale, for treatment of possible neonatal sepsis when administered in the community by female community health volunteers.
Introduction
Neonatal sepsis is a significant public health concern; severe infection is responsible for about 26% of all neonatal deaths worldwide. 1 Differential signs of illness severity are difficult to recognize, especially in neonates, and the disease is often in an advanced stage when the newborn is brought to the attention of the health worker. Therefore, it is important that newborns with these infections receive immediate empiric treatment even before the infectious agent is known, and a strong emphasis must be placed on the urgency of recognizing and managing newborn infection. 2 Nepal has pioneered the successful implementation of community-based public health initiatives, 3 relying on the active participation of a large and unique cadre of workers, the female community health volunteers (FCHVs). These FCHVs are local married women who have been selected by their communities and mothers' groups for health promotion through the Ministry of Health and Population (MoHP). The FCHVs receive no payment for their services and volunteer their time to provide basic services and health education in their communities as the most peripheral cadre of health workers of the MoHP. In most districts of Nepal, there are nine FCHVs in each village development committee (VDC), and they provide their services within their catchment area. As per government of Nepal policy, there is one health facility in each VDC, and most often this is a subhealth post staffed by three health workersFan auxiliary health worker, a maternal and child health worker (MCHW) and a village health worker (VHW). The VHWs and MCHWs are the immediate supervisors of the FCHVs and support them in their work.
In 2004, the MoHP introduced a community-based pilot program, the Morang Innovative Neonatal Intervention (MINI) in a large district (population over 900 000) in the eastern terai (flatlands) of Nepal to address the high mortality attributed to neonatal sepsis. 4 The MINI program trained and supported the FCHVs to visit homes in their villages within 24 h of birth to weigh newborns, prepare a simple record of the birth, assess the neonates for any danger signs of infection and alert mothers and caretakers to call her immediately for reassessment if any danger signs occur. Through MINI, FCHVs in Morang have also been trained to identify and initiate management of both local bacterial infections and possible severe bacterial infections (PSBI) in young infants (0 to 59 days of age), using an appoach similar to what has been used in India. 5, 6 For all newborns regardless of weight, the FCHVs conducted an initial clinical assessment, using an algorithm to identify any danger signs. The following 10 danger signs were included in the algorithm: Identification of any one danger sign resulted in immediate treatment by the FCHV with oral cotrimoxazole-p (dissolved in breast milk). FCHVs then provided the family with cotrimoxazole-p to be administered twice daily at home for a total of 5 days. FCHVs would also give the family a 'call form' to take to the next level of health worker (VHW, MCHW or auxilary health worker) to request once-daily injections of gentamicin for 7 days in the baby's home.
The MINI model for treating PSBI appears to be feasible in a flatland district where accessibility is reasonably good (usually less than a 30-min walk between health facility and the home of the sick infant). It may be difficult or impossible to implement this model of care in the hill and mountain districts of the country and achieve similar coverage. The compliance with referral may be limited by inaccessibility of health facilities in these districts. Therefore, exploring the feasibility of alternative models of careF such as the use of gentamicin in the Uniject prefill injection sytem (Uniject is a trademark of BD (Franklin Lakes, NJ, USA); hereafter referred to as Uniject)Fin areas that are less accessible such as the hill and mountain region is of interest. The objective of this particular study was to explore the feasibility and acceptability of gentamicin in Uniject in combination with oral cotrimoxazole and an appropriate newborn weighing scale for treatment of possible neonatal sepsis when administered in the community by FCHVs.
Methods

Study design and procedures
This study was a post-test-only, non-experimental research design aimed towards assessing the feasibility of gentamicin in Uniject when used by FCHVs in a peripheral care setting. Newborn infants up to 59 days of age that weighed <3500 g and who were suspected of having PSBI as per the standardized diagnostic protocol/ algorithm were treated with gentamicin and oral cotrimoxazole-p as per the MINI project standard of practice. The novel intervention being assessed in this study was the delivery of gentamicin via Uniject by FCHVs under the supervision of health workers (MCHW, VHW or health facility worker in-charge (HFW)). Five VDCs in Morang District with high birth rates and political stability were selected for inclusion in the study. VDCs with a high volume of PSBI episodes (per the MINI database) were selected to maximize the likelihood of having adequate cases.
Eligibility inclusion criteria for the four groups of participants (health workers, sick young infants, caretakers of sick young infants and local community leaders) included: For the purposes of this study, PSBI was defined in the same way as in the regular MINI study described earlierFas the presence of any one of the 10 danger signs. If the FCHV assessed the sick young infant as having PSBI, she initiated treatment with cotrimoxazolep and supplied the family with cotrimoxazole-p to be administered twice daily at home for a total of 5 days. For the first case any FCHV treated after her training, she filled a 'call form' to request her immediate supervisor to come to the baby's home to observe the FCHV administering gentamicin in Uniject. The supervisor observed all seven doses for the first case. For subsequent cases, after initiating treatment with cotrimoxazole-p, the FCHV administered the first dose of gentamicin in Uniject and called the supervisor to observe the second dose. The remaining doses were given by the FCHV, unsupervised. The FCHVs administered gentamicin in Uniject to sick newborns at home by safe, therapeutic gentamicin dosing regimens identified for use in Uniject to treat neonatal sepsis in developing country settings (Table 1) . 7, 8 FCHVs determined infant weight by using their color-coded Salter scale. Packages of gentamicin in Uniject were color coded the same as the scale to facilitate identification of proper dosing regimen. Babies weighing over 3500 g were referred to the health facility for treatment with gentamicin delivered in a standard syringe by an HFW, VHW or MCHW. The study protocol was reviewed and approved by the Nepal MoHP, the Nepal Health Research Council and the Program for Appropriate Technology in Health (PATH) Research Ethics Committee.
Materials
The Uniject prefilled, single-dose injection system (The Uniject injection system was developed and advanced by PATH under the United States Agency for International Development (USAID)-supported HealthTech program. It was licensed to BD in 1996.) combines medication, syringe and needle in a small, sterile package ( Figure 1 ). Uniject was specifically designed to make injections safe and easy to administer, especially by minimally trained health workers at locations outside the health facility. Uniject, prefilled with a single gentamicin dose, may be easily transported and used in a home or primary health facility when the signs of a neonatal infection are first detected. Health workers may be trained to use gentamicin in Uniject to extend accessibility and facilitate administration of antibiotics for early treatment of neonatal infections. Home-based and primary health facility use of gentamicin in Uniject is considered highly feasible based on previous experience introducing Uniject in various developing countries. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] Other materials used in the study included a color-coded scale (Salter Housewares, Oak Brook, IL, USA) with three different weight categories to weigh infants, a flat mercury thermometer to assess infant temperature, a simple timer to count infant respiratory rate and a safe disposal box for used Unijects. A small disposal box for each sick infant was used to discard Unijects used in treatment.
Data collection and analysis
Mixed methods were used to collect data related to Uniject performance, acceptability, safety and disposal. Data were collected between January and June 2009. Before the intervention, health worker competency in administering gentamicin in Uniject was assessed using structured questionnaires, observation and skills checklists. During the intervention, health workers recorded treatment data in the registers designed for this purpose. After the intervention, semistructured questionnaires and focus group discussions with FCHVs and in-depth interviews with supervisors (MCHWs, VHWs and HFWs) and caretakers of infants who had been treated by FCHVs using gentamicin in Uniject were conducted to assess perceptions, feasibility and acceptability of use of gentamicin in Uniject, including interest in using Uniject in the future. Acceptability measures were rated on a four-or five-point Likert scale.
Data cleaning, coding, entry and preliminary analysis was conducted in Nepal. Univariate and bivariate analysis of key quantitative variables was conducted using SPSS 16.0. Mean scores were calculated for ordinal acceptability data. w 2 tests were performed to determine whether the acceptability measures were statistically different. Notes were taken manually during all focus group discussions/in-depth interviews. Coding was carried out following the translation of the transcribed data set. A set of codes was developed and quantitative data were sorted and analyzed thematically.
Results
A total of 45 FCHVs participated in this study. In addition, in-depth interviews were conducted with 12 supervisors (MCHWs, VHWs and HFWs) and 45 caretakers of infants who had been treated by FCHVs using gentamicin in Uniject. All specific comments noted reflect generalized topics of discussion that were raised by all FCHVs raised during five focus group discussions at the end of the intervention period.
During the study period, FCHVs recorded a total of 422 live births and treated 67 of the 82 PSBI infants first seen by them with gentamicin in Uniject and referred 15 cases to the health facility. In all, 14 infants were referred to the health facility because their weight was more than 3500 g, and one family refused treatment and took the baby to the larger hospital in the district center. Among the 67 cases treated by FCHVs, 62 were normal weight, 4 were low weight and 1 was very low weight. The very-low-weight infant was recommended for referral but did not comply, so this infant was treated by the FCHV.
Outcome of PSBI treated by FCHVs A 100% completion rate for both cotrimoxazole-p and gentamicin in Uniject was achieved in all 67 cases treated by FCHVs. No deaths were reported, and all 67 cases improved by the last day of treatment with gentamicin in Uniject. There was no local reaction observed apart from mild redness at injection site in two cases. All 33 first cases treated by FCHVs were supervised everyday for 7 days by their immediate supervisors, and the remaining 34 cases were all supervised for the second dose. In all 67 cases, the FCHVs followed the correct disposal of used gentamicin in Unijects by placing them in the disposal box without recapping and returning the disposal boxes to their respective supervisors. Figure 1 The Uniject prefilled, single-dose injection system.
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Median time lags for the first FCHV visit to sick young infants and between onset of illness and first dose of gentamicin in Uniject was approximately 2 days. Most (82%) sick young infants received their first dose of gentamicin in Uniject on the same day as their first contact with the health workers.
Acceptability of gentamicin in Uniject by FCHVs
Acceptability of gentamicin in Uniject was high among both FCHVs who did and did not treat PSBI (Table 2) . No statistically significant differences were noted between these two groups in their experience of the performance or in their desire to use gentamicin in Uniject in the future.
FCHVs in all five focus group discussions expressed confidence in their selection of the correct dose of gentamicin in Uniject. Selecting the correct dose required the FCHVs to weigh the baby, identify the newborn's color-coded weight category and then match the newborn's weight category with the appropriate gentamicin in Uniject dosing regimen. They attributed their confidence to their previous training through the MINI project in weighing babies and to the color coding of the gentamicin in Uniject packages that corresponded to their dose administration chart.
The majority of FCHVs (87%) reported storing the gentamicin in Uniject in tin boxes, whereas others stored it in carry bags (9%), cupboards (2%) or polythene bag (2%). They felt these boxes ensured safe storage as neither children nor vermin such as rats could access the gentamicin in Uniject.
No needle stick injury occurred during the study, and the FCHVs correctly disposed of all the used Unijects in a disposal box without recapping them.
Perception of burden by FCHVs
FCHVs who treated sick young infants using gentamicin in Uniject spent an average of 8 h per week including travel and time for injections. During the focus group discussions, the FCHVs identified several challenges in their work to treat sick newborns. These included: (1) traveling to the home of the infant to treat for seven consecutive days is a burden both in terms of time and distance; (2) concern about their liability if the infant they are treating dies; and (3) concern that community members think they are receiving payment for their services. Of the 33 FCHVs who treated PSBI cases with gentamicin in Uniject, 31 did not perceive giving gentamicin in Uniject as an extra burden.
The largest challenge that participants faced in using gentamicin in Uniject related to their level of confidence using the Uniject system, especially for the first time. All FCHVs described scenarios that provoked fear or concern for them. They were afraid that: (1) the injection would result in wound or local infection at injection site; (2) the injection would be given in the wrong location or hit the bone; (3) the health status of the baby would not improve after the first injection; (4) the family of a sick newborn would be unhappy or dissatisfied if the health of the newborn did not improve; (5) the administration of seven injections would harm the newborn; or (6) the full treatment could not be given to the newborn because the FCHV or the newborn was not at home.
Satisfaction with community-based treatment using gentamicin in Uniject Of the 12 (92%) supervisors (HFW/VHW/MCHW) interviewed, 11 were satisfied with FCHVs giving gentamicin in Uniject. The supervisors thought that this would decrease their own workload, and the communities would receive prompt treatment with services brought closer to home. They stated that the FCHVs were well trained, which built trust in the communities. Similarly, caretakers expressed their satisfaction with the treatment model. In all, 95% of caretakers of sick infants treated by FCHVs using gentamicin in Uniject were satisfied with the services provided by the FCHVs. They stated that since the FCHVs reside in the communities, services can be brought closer to home and they can receive prompt treatment from a familiar person. Caretakers also appreciated that they could receive services at home that were free of cost. These themes were repeated in the focus group discussions with FCHVs. Focus group discussion participants reported that families of infants who received treatment were satisfied with their services. For the most part, families accepted the FCHVs as people who are skilled and knowledgeable to treat their sick newborns and perceived that infant health status improved after treatment with gentamicin in Uniject. In addition, families preferred community treatment over facility treatment because of the availability of treatment at any time and availability of treatment in the home, thereby reducing the necessity to travel to a health facility. Of all cases treated by FCHVs, only one family refused treatment. The father of the infant was working abroad and the family was afraid that he might be unhappy if the infant was treated at home.
In all, 80% of the caretakers of sick infants treated with gentamicin in Uniject stated that they preferred FCHVs as their service provider and said that FCHVs will be their first choice for treatment if their baby is sick. Other treatment sources are government health facilities (subhealth posts or health posts in their villages, primary health-care centers or the larger hospital in the district center or private clinics of local paramedics or doctors in the district centre). Families that choose these types of providers would generally incur higher costs, more travel time and more time away from their work and home.
Discussion
This study was conducted in Morang district where the FCHVs and supervisors were already experienced in managing neonatal infections in the community. The FCHVs were already trained to measure weight, temperature and respiratory rate, and to classify neonatal infection using an algorithm containing 10 danger signs. The treatment protocol for this intervention was continued from the existing MINI program, which included use of oral cotrimoxazole-p and gentamicin injection for possible infection in newborns. The study was not intended to explore the safety of cotrimoxazole and gentamicin, but was based on the safety of the drugs as demonstrated in studies in India. 6 The gentamicin in Uniject injection was the only new skill added for the purpose of this study.
Overall, the gentamicin in Uniject injection system functioned well in terms of acceptability and performance among health workers. Given this, it appears that gentamicin in UnijectFin combination with oral cotrimoxazole and an appropriate scaleFis a feasible option for the treatment of possible neonatal sepsis when administered at home by FCHVs. Further, the FCHVs were motivated about using gentamicin in Uniject and demonstrated their ability to use this treatment modality in a program setting. Health workers demonstrated their ability to use gentamicin in Uniject in combination with an appropriate scale, including choosing the correct dose and dosing schedule and adhering to a correct dosing schedule. Finally, administration of gentamicin in Uniject by FCHVs as a treatment for possible neonatal sepsis was highly acceptable to caretakers of sick young infants who had been treated with the injection system.
The use of this community-based treatment model appears to have a positive impact on the government health system. The peripheral government health workers involved in this study recommended that this treatment model be continued and replicated in other districts of the country. Morang, where the gentamicin in Uniject study was implemented, is in the flatlands with relatively easy access compared with the hilly and mountainous region of the country. On the basis of our experience, we believe that hill and mountain areas should be the target regions for implementing scale up of gentamicin in Uniject because of its ability to reduce barriers to treatment access. The simplicity and ease of use of gentamicin in Uniject would likely contribute to increased coverage of neonatal sepsis treatment in settings where referral is not a viable option.
In this study, the supervisors of the FCHVs were required to be present to observe administration of all doses of gentamicin in Uniject for the first case and the second dose for subsequent cases. In this geographical setting they did not find this difficult, but it did contribute to a delay in the onset of treatment for the first case, as the FCHV had to wait for the supervisor before giving the gentamicin in Uniject to the sick young infant. Supervisory models that have VHWs/MCHWs supervise all doses of the first case treated by the FCHV may not be feasible in hill/mountain regions. This suggests that the use of a peer support network for FCHVs, possibly through using cell phones, may be appropriate to build confidence for individual case management. For example, in geographically remote areas, cell phones could be used to inform the health worker about the sick young infant. Cell phone communication with another FCHV or health worker could be very useful in building the confidence of FCHVs to treat sick newborns independently. Future operations research is warranted to assess the effect of implementation of gentamicin in Uniject in hill/mountain regions, including need and frequency of initial and refresher training.
The cost of the injection system will be a determining factor in potential scale up. Gentamicin in Uniject is a prefilled injection system that simplifies dosing and integrates reuse prevention; it will always be more expensive than gentamicin in an ampoule delivered with a needle and syringe. Current cost estimates from the manufacturer range from US$0.80 to US$1.00 per dose (similar to other prefilled injection devices). This estimate does not include the additional cost of making it available within the country, such as transportation, local taxes and distributor margin. This added cost should be considered within the context that the simplicity of the intervention allows for minimally trained and supervised community health volunteers to provide this lifesaving treatment to newborns in communities that would otherwise not be reached. This community-based approach to treat possible newborn infection could be a promising intervention in countries where access to quality health services is limited. This approach not only saves lives but also increases compliance with completion of a course of antibiotics. Our experience suggests that successful implementation of this intervention would be more likely when a trained community-based cadre and monitoring system are already established.
A limitation of this study is that it was not comparative in design and had no control group to demonstrate the effect of the intervention. An exploratory pretest/post-test design such as this was appropriate, however, given that this study explored initial feasibility of the Uniject injection system performance. Further, this study was limited to one district in Nepal that had experience in community-based sepsis management. It is possible that results of this study cannot be generalized to other areas that are not experienced in community-based sepsis management strategies.
